SMAD5 and urinary bladder cancer: Jointly, our study served as a proof that KCNMB2-AS1 may act as an oncogenic lncRNA to stimulate the development of cancer through miR‐3194-3p/SMAD5 pathway and enjoy a great possibility to be a therapeutic target and promising biomarker for bladder cancer.